Zynex Inc. (ZYXI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q3 2024 Earnings Conference Call October 24, 2024 4:15 PM ET Company Participants Quinn Callanan - IR Thomas Sandgaard - Chairman, President and CEO Dan Moorhead - CFO Donald Gregg - President, Monitoring Solutions Conference Call Participants Avi Dahan - RBC Capital Markets Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.
Zynex sees pain management orders increase in Q3 following FDA approval
Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net revenue of $50 million for the quarter ended September 30, 2024, up slightly from $49.9 million in the prior-year period.
Sales, strategy, and saving lives: A conversation with Zynex CEO Thomas Sandgaard
Thomas Sandgaard is just getting started. The enigmatic “rockstar CEO” of pain management company Zynex Inc (NASDAQ:ZYXI) has worn many hats throughout his career: Sales leader, lead guitarist, football club owner (pro tip: dealing with shareholders is much easier than dealing with sports fans).
Zynex's strategic shifts set stage for long-term success, analysts say
Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initiatives are seen as laying the groundwork for long-term success despite short-term hurdles.
Zynex CEO reflects on 28 years of medical device innovation - ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory. Sandgaard highlighted how Zynex has expanded from a one-person operation 28 years ago to a company with 1,200 employees and revenues reaching $200 million.
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Zynex pain management device TensWave achieves FDA clearance
Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which the company highlighted has been clinically proven to reduce chronic and acute pain without needing medication.
Zynex's bold expansion in patient monitoring technologies moves from vision to reality
Growth versus value: It's a classic dilemma for investors. Choosing growth often demands a leap of faith—buying into a management team's vision of a significant commercial opportunity that may require patience and substantial financial investment to realize.
Why Zynex Plunged Today
Zynex missed on second-quarter revenue and earnings, and guided down. However, some of the near-term weakness was by design, as the company is cutting costs.
Why Is Zynex (ZYXI) Stock Down 24% Today?
Zynex (NASDAQ: ZYXI ) stock is falling on Friday following the release of the medical device maker's earnings report for the second quarter of 2024. This starts with diluted earnings per share of 4 cents.
Zynex, Inc. (ZYXI) Q2 2024 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2024 Earnings Conference Call July 23, 2024 4:15 AM ET Company Participants Thomas Sandgaard - Chairman, President & Chief Executive Officer Dan Moorhead - Chief Financial Officer Donald Gregg - President, Zynex Monitoring Solutions Quinn Callanan - MZ North America Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex Second Quarter 2024 Earnings Conference Call.
